

**Comparison between Men and Women of Volume Regulating Hormones and Aquaporin-2**

**Excretion following Graded Central Hypovolemia**

Nandu Goswami<sup>1\*</sup>, Johannes Reichmuth<sup>1\*</sup>, Annarita Di Mise<sup>2</sup>, Bianca Brix<sup>1</sup>, Andreas Roessler<sup>1</sup>,  
Mariangela Centrone<sup>2</sup>, Marianna Ranieri<sup>2</sup>, Annamaria Russo<sup>2</sup>, Natale G. De Santo<sup>3</sup>, Grazia  
Tamma<sup>2</sup>, Ferdinando Carlo Sasso<sup>3\*\*</sup>, Giovanna Valenti<sup>2\*\*</sup>

1. *Physiology Division, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Austria*

2. *Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari Aldo Moro, Italy*

3. *Dept. of Medicine, Surgery, Neurology, Metabolism and Geriatrics, School of Medicine and Surgery, Università della Campania L. Vanvitelli, Italy*

\* *Both co-authors contributed equally to the manuscript*

\*\* *Corresponding author*

Prof. Giovanna Valenti

Department of Biosciences, Biotechnologies and Biopharmaceutics

University of Bari Aldo Moro, Via Orabona, 4, 70125 Bari - Italy

Phone: +39-080-544.3444; Fax: +39-080-544.3388

e-mail: [giovanna.valenti@uniba.it](mailto:giovanna.valenti@uniba.it)

**Or**

Prof. Ferdinando Carlo Sasso, *MD, PhD*

Dept. of Medicine, Surgery, Neurology, Metabolism and Geriatrics

School of Medicine and Surgery

Università della Campania "L. Vanvitelli", viale Lincoln, 5 - 81100 Caserta (CE), Italy

office: +39-081-5665010; mobile: +39-335-5890271

e-mail: [ferdinando.sasso@unicampania.it](mailto:ferdinando.sasso@unicampania.it)

## **ABSTRACT**

Central hypovolemia induced by orthostatic loading causes reno-vascular changes that can lead to orthostatic intolerance. In this study, we investigated volume regulating hormonal responses and reno-vascular changes in male and female subjects as they underwent central hypovolemia, induced by graded lower body negative pressure (LBNP). Aquaporin-2 (AQP2) excretion was measured as a biomarker for the renal system response to vasopressin.

37 young healthy subjects (n = 19 males; n = 18 females) were subjected to graded LBNP until -40 mmHg LBNP. Under resting conditions, males had significantly higher copeptin (a stable peptide derived from vasopressin) levels compared with females. Adrenocorticotropin (ACTH), adrenomedullin (ADM), vasopressin (AVP) and brain natriuretic peptide (BNP) were not affected by our experimental protocol. Nevertheless, an analysis of ADM and BNP with the data normalized as percentages of the baseline value data showed an increase from baseline to 10 min after recovery in the males in ADM and in the females in BNP.

Analysis of BNP and ADM raise the possibility of a preferential adaptive vascular response to central hypovolemia in males as shown by the normalized increase in ADM, whereas females showed a preferential renal response as shown by the normalized increase in BNP. Furthermore, our results suggest that there might be a difference between men and women in the Copeptin response to alterations in orthostatic loading, simulated either by using LBNP or during posture changes.

*Keywords:* orthostatic loading, lower body negative pressure, vasopressin, copeptin, adrenomedullin, aquaporins.

## **LIST OF ABBREVIATIONS**

ACTH: Adrenocorticotrophic Hormone

ADM: Adrenomedullin

ANP: Atrial Natriuretic Peptide

AQP2: Aquaporin 2

AVP: Arginine-Vasopressin

BNP: Brain Natriuretic Peptide

CVP: Central Venous Pressure

HUT: Head Up Tilt

LBNP: Lower Body Negative Pressure

RAAS: Renin-Angiotensin-Aldosterone System

## INTRODUCTION

### *Hormonal responses and cardiovascular regulation*

Arginine vasopressin (AVP), is a nonapeptide secreted from the posterior pituitary in response to hyperosmolality, hypotension and hypovolemia (Bichet 2016). It controls water body homeostasis acting through the vasopressin receptors V1a, V1b and V2. AVP plays a key role in the pathophysiology of orthostatic intolerance being involved in modulating blood volume regulation (Hinghofer-Szalkay et al. 2011). In this respect, it has been shown that plasma AVP significantly increases at the point of presyncope that is characterized by the end of cardiovascular stability (Hinghofer-Szalkay et al. 2011). Repeated orthostatic intolerance episodes may occur with high incidence in older persons who often have increased plasma AVP levels although the kidney response to AVP may be decreased (Tamma et al. 2015). The actual role of AVP under conditions of orthostatic loading that do not lead to presyncope remains to be clarified.

Copeptin, first described in 1972 by Holwerda, can be considered a surrogate biomarker for plasma AVP (Holwera 1972, Mohanty et al. 2015). Copeptin is the C-terminal part of pre-vasopressin that is formed by a signal peptide, arginine vasopressin, neurophysin-II and copeptin. Copeptin is co-synthesized with AVP and secreted in equimolar amounts with AVP (de Bree et al. 1998). AVP consists of 9 amino acids and has a molecular weight of approximately 1000 Dalton while Copeptin is a 39 aminoacid glycopeptide with a molecular weight of 5000 Dalton (Nickel et al. 2012). Physiologically, Copeptin may be involved in AVP maturation (Barat et al. 2004) and is more stable *in vivo* and *ex vivo* than AVP (Dobsa et al. 2013, Koch et al. 2015, Schnyder et al. 2015). In contrast, plasma AVP is unstable, largely bound to platelets and rapidly clearing making its measurement process difficult and inaccurate.

Adrenomedullin (ADM), a 52-aminoacid-peptide first discovered in 1993 in Pheochromocytoma tissue, is secreted from smooth muscle cells and vascular endothelium. ADM plays a role in the regulation of blood pressure at short-term (Wong et al. 2012, Angeletti et al. 2015). Moreover, evidence also suggest that ADM is involved in the short-term adaptation to orthostatic loading at least in male subjects (Rössler et al. 1999). However, no data on the putative role of ADM in females under conditions of orthostatic loading not leading to presyncope are available.

Brain natriuretic peptide (BNP), a polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (Hunt et al. 1995, Rademaker et al. 2005), has a physiological action similar to that of atrial natriuretic peptide (ANP). It plays important roles in decreasing systemic vascular resistance and central venous pressure as well as increasing natriuresis. It consists of 32 amino acids cleaved from a pro-hormone called N-Terminal pro-hormone of BNP (NT-pro BNP). BNP plasma levels correlate with the severity of congestive heart failure. Unsurprisingly, BNP and NT-pro BNP are used as a diagnostic marker for treatment of heart failure (Kato et al. 2005, Suzuki et al. 2001, Janda et al 2010). Despite BNP being first isolated from the brain, it is primarily secreted in the ventricles (Rose 2000). Furthermore, recent studies have shown that some patients with idiopathic orthostatic hypotension have a significant elevation of NT-pro BNP (Krishnan et al. 2015). Accordingly, BNP release is triggered by a rise in preload (Kato et al. 2005). To what extent, however, does central hypovolemia, as induced by prolonged hemorrhage or LBNP application is currently not known but needs to be investigated.

#### *Sex, orthostatic loading and vasoactive hormones:*

Women have a lower orthostatic tolerance than men and a higher incidence of orthostatic hypotension as well as vasovagal syncope (Convertino et al. 1998, Meendering et al. 2005, Fu et al. 2004, Franke et al. 2003, Waters et al. 2002, White et al. 1996, Alboni et al. 2014) . The exact physiological mechanisms, underlying the lower orthostatic tolerance in females, are not yet clarified. AVP may play a role in orthostatic tolerance difference across sex as men show higher AVP plasma levels and a higher urine concentrating ability than women (Roussel et al. 2014). Further, the secretion pattern of AVP is dependent on the phase of the menstrual cycle (Vokes et al. 1988, Forsling et al.1982, Stachenfeld et al. 1998). While the lower orthostatic tolerance in females may also be associated with an increased splanchnic blood pooling due to lower vasoconstriction and a lower total peripheral resistance during central hypovolemia (Jarvis et al.2010, Russomano et al. 2015), the role of hormones across sex during central hypovolemia not leading to presyncope remain to be investigated.

### *Lower body negative pressure (LBNP)*

To examine the effects of central hypovolemia on the human body the use of lower body negative pressure has long been established (Goswami et al. 2008). It consists of a chamber in which the lower body of the supine subject is placed and which is then made airtight. Negative pressure is then build up within the chamber, to cause a fluid shift into the lower body and thus simulate the central hypovolemia that is also induced by changes in posture from supine to standing.

In the present study, we investigated the effect of graded LBNP not leading to presyncope on plasma copeptin, AVP, ADM and BNP in both sexes. We also evaluated the effect of LBNP on Aquaporin 2 (AQP2), a water channel regulated by AVP in part excreted in the urine (u-AQP2) that can be considered a biomarker the renal response to AVP. We hypothesized that central hypovolemia – induced using graded lower body negative pressure- leads to a significant alteration in the hormones and across sex. We also hypothesized that there is a correlation between plasma Copeptin and plasma AVP and that there is also a correlation between u-AQP2 changes and changes in Copeptin and AVP.

### **Methodology**

*Participants (for subjects characteristics see Table 1):*

Participants (n = 19 males; n = 18 females) were recruited using following specific criteria. Inclusion criteria were ages between 18 and 35 years and height between 160 and 180 cm. Exclusion criteria were pregnancy, smokers and endurance athletes, as they are associated with reduced orthostatic tolerance (Levine et al. 1991), subjects with history of orthostatic intolerance or those with cardiovascular or renal disorders or those taking any medication affecting the cardiovascular system. The subjects were instructed to abstain from caffeine and alcohol consumption 24 hours prior to the experiments. The experiments were conducted at the Medical University of Graz between 8 am – 2pm during April and May 2015.

### *Experimental protocol*

The experimental protocol is summarized in Figure 1. Each experiment started with the subject being placed on the LBNP table (Figure 2). The first stage consisted of a 30-min. Supine resting period during which the monitoring equipment was placed on the participants. LBNP was applied at the beginning with -10 mmHg and increased by -10mmHg in five-minute intervals until a maximum of - 40mmHg LBNP. This was followed by another ten-minute recovery period following LBNP (Figure 1).

Blood pressure, heart rate, stroke volume and total peripheral resistance were monitored using a Task Force ® Monitor (CNSystems, Graz, Austria). Development of presyncope such as sharp drop in blood pressure or heart rate, sudden increase in sweating, nausea, dizziness were criteria for terminating the experiment. Furthermore, subjects could terminate the experiment by using a button settled under the right hand. Subjects who experienced presyncope were excluded from hormone analysis due to the study being specifically designed to examine orthostatic loading not leading to syncope. Blood samples were taken in minutes 28, 48 and 58 from a vein in the antecubital fossa with a 17G, 1.4 · 40 mm Teflon ® cannula. Urine was collected 24-hour before the experiment and at the end of the recovery period following LBNP application.

### *Urinary AQP2 measurements by ELISA (enzyme-linked immunosorbent assay)*

Urinary AQP2 excretion was measured in the urine samples by ELISA as previously described (Tamma et al. 2014). Briefly, urine samples were spun at 3,000 rpm for 10 min at 4°C to remove cellular debris in the presence of the protease inhibitors (1 mM PMSF, 2 mg/ml leupeptin, 2 mg/ml pepstatin A). 5 µl of urine sample were diluted to 50 µl in PBS containing 0.01% SDS, placed in a MaxiSorp 96-well microplate and incubated overnight at 4°C. In parallel wells, increasing concentrations (50, 100, 200, 300, 400, 500 and 1,000 pg/50 µl) of a synthetic peptide reproducing the last 15 amino acids of the C-terminal region of human AQP2 were incubated as internal standard. Wells were washed with a washing solution of PBS containing 0.1% Tween20 and incubated with blocking solution (PBS - 3% BSA) at room temperature for 1 hour. 10 µg of affinity-purified anti-AQP2 antibodies were diluted in blocking solution and 50 µl of the solution was added to each well and incubated for 2 hours at 37°C. Wells were then washed with washing

solution and incubated with secondary goat anti-rabbit antibodies conjugated to horseradish peroxidase for 1 hour at 37°C. After five washings with washing buffer, 50 µl of the substrate solution [2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)] were added to each well and incubated for 30 minutes in the dark at room temperature. Absorbance was measured with a microplate reader (model iMark, Bio-Rad Laboratories, Milan, Italy) at 405 nm. Urinary AQP2 excretion was expressed as fmol/mg urine creatinine. Urinary AQP2 measurements took place at the Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari Aldo Moro, Italy.

### *Hormone measurements*

Hormones were measured from blood plasma. Blood samples were collected into chilled plastic tubes with disodium-EDTA and aprotinin. The tubes were placed on ice prior to centrifugation at  $1,600 \times g$  for 15 min at 4°C to collect the plasma and stored at -80°C immediately until further processing. No sample was thawed more than 2 times.

ACTH and BNP were measured by a competitive inhibition enzyme-linked immunosorbant Assay (Cloud-Clone Corp.) following the manufacturer's instructions with a detection limit, which was less than 4,7pg/ml and 9,2 pg/ml, respectively. Copeptin and adrenomedullin were measured by a commercially available ELISA (Cloud-Clone Corp.) with a sensitivity less than 6,1pg/ml and 4,9pg/ml, respectively. AVP was measured by ELISA, the materials of which were made by ALPCO and ordered via Biomedica. Only samples measured using the same assay kit for a given hormone were included in the analysis in order to avoid a statistical bias due to differences among kits. All hormone measurements took place at the Physiology Division, Medical University of Graz, Austria.

### *Statistical analysis*

For the statistical analysis the current version 7 of the program Graphpad Prism published by Graphpad Software Inc. was used.

Hormones were analyzed using a 2-way ANOVA to examine the influence of both sex and LBNP on hormone values as well as a possible interaction effect of both factors. A p-value of

$p=0.05$  was deemed significant and a  $p$ -value of  $p=0.01$  as highly significant. If a significant effect of sex or LBNP was observed, a D'Agostinho-Pearson normality test was performed on the data. If the normality test determined the data as non-normally distributed ( $p=0.05$ ), a non-parametric test was used for pairwise comparisons of the protocol stages and for inter-sex comparison. If the data passed the normality test Student's  $t$ -test was used for pairwise comparison. Non-Parametric tests were the Mann-Whitney U test for independent data sets, i.e. for comparison of men and women at a given protocol stage and the Wilcoxon test for paired data sets, i.e. for comparisons of the different protocol stages for a given sex. Furthermore, a regression analysis was performed for AVP and Copeptin using Spearman's rank coefficient in order to examine the relation between these two closely connected hormones.

## Results

Of the subjects examined 1 male and 2 female subjects experienced signs of presyncope and were thus excluded from hormone analysis. Hormonal data from other subjects which completed the protocol are shown in Table 2.

### 1. Hormones (Table 2)

#### *AVP, ACTH, ADM and BNP:*

A 2-way ANOVA did not yield any significant effect of protocol stage or of sex on either AVP, ACTH, ADM or BNP. No significances were seen when the data from subjects in their follicular and luteal phase were pooled together or examined separately (as two groups) and compared with each other and/or with the male subjects.

However, an analysis of ADM and BNP with the data normalized as percentages of the baseline value data showed an increase from baseline to 10 min after recovery in the males in ADM and in the females in BNP (both with  $p=0,05$ ) using a t-test while no significant change was observed in the respective other sex (not shown). However, this result was obtained including the presyncopal subjects and is subject to a possible distortion due to the absence of data regarding the effect of presyncope on ADM and BNP respectively. Furthermore, no post-hoc correction was used for the t-test.

#### *Copeptin:*

Our analysis showed a significant effect of sex ( $p=0.0196$ ) and a highly significant effect of the protocol stage ( $p=0.0042$ ) on plasma copeptin (Figure 3 and Table 2). Males had a higher copeptin than females at all three protocol stages and copeptin showed a steady decrease in both sexes over course of the protocol, with arithmetic means at baseline 281.6 pg/ml in males compared to 199.7 pg/ml in females, at the end of the LBNP 236.2 pg/ml compared to 169.1 pg/ml and 211.9 pg/ml compared to 152.0 pg/ml at the end of the recovery period. These data suggest a clear downward trend of plasma copeptin levels in both sexes. The 2-way ANOVA did not show a significant interaction effect of sex and protocol stage on plasma copeptin. Both for men and for women a Wilcoxon test did not yield a significant change between baseline vs end of LBNP or end

of LBNP vs end of recovery. However, between baseline and end of recovery, there was a significant decrease with  $p=0.0195$  for women and a highly significant decrease with  $p=0.0034$  for men. A Mann-Whitney U test was used to compare the copeptin plasma levels of both sexes at baseline and at the end of the recovery period showing being significant with  $p=0.0270$  at baseline and highly significant with  $p=0.0035$  at the end of the recovery period, thereby indicating that the decrease in plasma copeptin over the course of the experiment was overall greater in women than in men. Thus, we observed a decrease in plasma copeptin in both sexes over the course of the experimental protocol, and a higher copeptin in men than in women, a difference which became more pronounced over the course of our experiment.

A regression analysis was also conducted to assess correlation between copeptin and AVP. Spearman 's rank correlation coefficient yielded a value of 0.118 at baseline, 0.170 at the end of LBNP and 0.237 at the end of the recovery period with a p level of well over 0.1 in all three cases. These data show no significant correlation between AVP and copeptin.

## 2. Aquaporins

u-AQP2 was measured in all subjects. In basal conditions, u-AQP2 levels in the 24-hour urine samples were significantly higher in females ( $n=18$ , 4762 +/- 338.8 fmol/mg) than in males ( $n=19$ , 2756 +/- 282.7 fmol/mg; \*\*\* $p<0.0001$ , Figure 4A). After 10 min recovery from LBNP, u-AQP2 levels were not significantly different in both sexes, remaining significantly lower in males as compared to females after the LBNP (Figure 4B, \*\*\* $p<0.0001$  vs females initial, \*\* $p<0.001$  vs females final, unpaired t-test).

## Discussion

The present study identified the renal-vascular changes in response to central hypovolemia induced by graded lower body negative pressure by measuring blood volume regulating hormones in healthy males and females, at rest and after 10 min of recovery post-LBNP. No significant changes and no sex differences in ACTH or AVP were observed. Copeptin decreased from baseline to the end of the recovery period. Males had significantly higher copeptin values than females, a difference that was more pronounced at the end of the recovery period than at baseline, thereby suggesting a difference in copeptin response in our experimental protocol. BNP showed an increase from baseline to the end of the recovery period only in females and only when the data were normalized as percentages of the baseline value. Similarly, ADM showed an increase from baseline to the end of the recovery period only in males and only when the data were normalized as percentages of the baseline value. Urinary AQP2 was significantly higher in females and showed no significant change.

Under conditions of central hypovolemia, intravascular blood volume variations are sensed by vascular volume- and baroreceptors, which control the antidiuretic hormone arginine vasopressin (AVP) release, whose action induces water retention and contributes to osmotic and cardiovascular homeostasis. AVP is a peptide hormone consisting of 9 amino acids, synthesized as part of a larger precursor molecule in the nuclei of the hypothalamus, stored in vesicles within the cytosol, transported down the axons and stored within the neurons close to the nerve endings in the posterior lobe of the pituitary (Koshimizu et al. 2012, Laycock 2010). During the transport, AVP is split from its precursor molecule, along with two other, larger molecules. The major stimulus for AVP release is an increase in plasma osmolality (1-2%) or a reduction of arterial volume (8-10%) (Wong et al. 2002). Circulating AVP is therefore orchestrated by the interplay between osmoreceptors and baroreceptors. A reduction of blood pressure detected by baroreceptor cells in the aortic arch triggers -via afferents of the glossopharyngeal and vagal nerves to the nucleus tractus solitarius and from there to the paraventricular nucleus- a release of AVP as part of the baroreceptor reflex (Norsk et al. 1993). The effects of AVP are almost exclusively mediated by three types of G-protein coupled receptors, the V1a (vascular) and V1b (pituitary) receptors which activate an Inositol-Triphosphate pathway and the V2 (vascular and renal) receptor, which work

through a cyclic adenosine monophosphate (cAMP) pathway (Koshimizu et al. 2012). In the renal collecting duct, AVP binding to the vasopressin receptor 2 (V2R) promotes water reabsorption by inducing redistribution of the water channel AQP2 from intracellular vesicles into the plasma membrane (Nedvetsky et al. 2009). This permits water entry into the cell and water exit through basolateral AQP3 and AQP4, resulting in the concentration of urine. Approximately 3% of the AQP2 expressed in renal collecting duct principal cells is excreted into urine through exosomes, small vesicles of 40-80 nm in diameter secreted into the urine by renal epithelial cells through the exocytosis of multivesicular bodies (MVBs). AQP2 excretion is proportional to its expression in the kidney and in the luminal membrane of renal collecting duct principal cells, representing a useful biomarker for water concentration diseases (Valenti et al. 2000). Specifically, an increase in AQP2 urine excretion derives from a higher translocation of the water channel to the membrane under vasopressin stimuli, whereas a reduced AQP2 excretion reflects its lower expression in the plasma membrane and the reduced renal ability to reabsorb water.

At vascular level, AVP exerts a vasoconstrictive effect, and specifically through the V1a receptors expressed in smooth muscle triggers release of  $Ca^{+2}$  ions intracellular stores resulting in contraction of muscle cells. AVP also promotes release of steroids and mineralocorticoids, stimulating ACTH release from the anterior pituitary and enhancing renin secretion as well as aldosterone action (Koshimizu et al. 2012). Under physiological conditions AVP levels are very low (0 to 3 pg/ml) and even the best assays are unable to quantify them in the low range of physiological values (the lowest threshold of most immuno assays is 0.5 pg/ml) (Bankir et al. 2017). Moreover, AVP is highly unstable and rapidly degrades *ex vivo* even when frozen at 20 °C (Morgenthaler et al. 2006). Copeptin (CPP), which is cleaved from the C terminal portion of the pro-vasopressin, the AVP precursor protein, has been suggested as a useful biomarker of AVP levels since it is present in an equimolar ratio to AVP and is stable even after 1 week of storage at room temperature (Repaske et al. 1997). Because of these features, using copeptin as surrogate of AVP, in this study, we found that copeptin blood levels are significantly higher in males compared with females. These data are in agreement with previous observations indicating that vasopressin plasma concentration is significantly higher in males than in females and indeed, vasopressin-mediated effects on renal and vascular targets are more pronounced in males than in females

(Wang et al. 1997, Stachenfeld et al. 1998). The sex difference in copeptin levels consisted of plasma copeptin roughly 40 % higher in males than in females. This almost exactly corresponds to the difference in AVP levels between the sexes reported in the literature (Share et al. 1988, Crofton et al. 1986, Roussel et al. 2014). The fact that in our experiment AVP analysis did not yield a similar result is from our point of view most likely due to its in-vitro instability and the difficulties in obtaining a precise measurement.

In our study, we observed a decrease in plasma copeptin with each stage of the protocol in both the sexes. This came as a surprise to us for three major reasons. Firstly, as outlined in the introduction copeptin is considered to be a surrogate marker for AVP. In our experiment, AVP did not show any significant change at all, while Copeptin did. Secondly, even the sex difference known to exist in AVP plasma levels, we could not confirm this in our experiment. However, copeptin did show a significant sex difference with plasma levels being significantly higher in men at all three protocol stages. Thirdly, LBNP causes a reduction in venous blood return to the heart, which, in turn, via a cardio renal reflex, leads to AVP release. Therefore, it was expected that copeptin would be highest at the end of LBNP with a subsequent drop at the end of the recovery period due to the venous return returning to normal supine levels after the end of LBNP. Instead we observed that in both sexes copeptin decreased steadily being highest at baseline and lowest at the end of LBNP.

Regarding the minimum LBNP level required to stimulate an AVP response current evidence is somewhat conflicting. Trimarco reported a very slight AVP increase in subjects which underwent -10 mmHg of LBNP for 20 minutes, a lower stimulus than our protocol using increasing levels of LBNP starting with -10 and ending with -40 mmHg (Trimarco et al. 1987). Goldsmith et al. in 1982 used an experimental protocol similar to ours, monitoring central venous pressure (CVP) instead of LBNP strength and reducing a baseline CVP of 7,2 mmHg to 3.8 mmHg for 10 minutes and then to 1.0 mmHg for another 10 minutes. Using a more recent study regarding the interaction between LBNP strength and reduction in CVP as a cross-reference this would amount to roughly -15 and -30 mmHg of LBNP, respectively. Goldsmith did not observe any significant change in AVP (Goldsmith et al. 1982, Johnson et al. 2014). Furthermore, in another experiment by Roessler and colleagues in 2011, even LBNP of as much as -55 mmHg for 30-minute periods with supine resting

periods between them did elicit an AVP response for the first two applications. The responses in AVP were only seen after the third LBNP period (Roessler 2011). Therefore, judging from the existing evidence it appears likely that our LBNP strength was too weak to elicit a AVP response strong enough to be detected or perhaps it could be attributed to the in-vitro instability of AVP.

It has been shown that supine to erect posture change as well as ambulation increase AVP levels (Cignarelli et al., 1986, Tsuchihashi et al. 1989). Furthermore, it has been shown that plasma AVP levels adjust rapidly within approximately 10 minutes upon posture changes (Pump et al, 1999). We observed Copeptin decreases even during central hypovolemia. We speculate that the most likely explanation for the decrease in copeptin during baseline could be due to the subjects lying in supine position for 30 minutes. While AVP is released in an equimolar fashion with copeptin - due to its short half-life of about 10 to 20 minutes while Copeptin has a much longer half life of about 40 minutes (Koch et al. 2015, Schnyder et al. 2015) – AVP should have reached a steady state even before the first blood sample was taken, while copeptin would still be decreasing. Therefore, the decrease in Copeptin may be attributed to the assumption of supine posture at the beginning of the experiment. Furthermore, the significant decreases in Copeptin measured after 10 min recovery from LBNP might be due to the expected fluid shifting back to the upper body. It should be noted in this respect that mean Copeptin as well as mean AVP at the end of LBNP was already lower than at baseline thus suggesting that LBNP levels used in this study did not affect Copeptin levels. This is further supported by the fact that we did not observe a significant correlation between AVP and Copeptin, something which would be expected immediately after a peak in equimolar AVP and Copeptin release.

An interesting observation is the fact that in our experiment the decrease in Copeptin from baseline to end of recovery was more significant in men than in women; a more significant decrease from baseline to the end of recovery in men ( $p < 0.01$ ) than in women ( $p < 0.05$ ) was seen as was a more pronounced sex difference at the end of recovery than at baseline ( $p < 0.05$  vs  $p < 0.01$ ). As the 2-way ANOVA did not show a significant interaction effect of sex and protocol stage, it is difficult to ascertain whether plasma Copeptin responses differ across sex or whether the observed differences were caused by LBNP application or due to 30 min supine posture assumption at the beginning of the experiment. Generally speaking, our data confirm that Copeptin

is of value as a surrogate marker for AVP measurement but that differences in plasma half-life must be considered with a sufficient baseline period necessary to allow plasma Copeptin to reach a steady state. This might be of special importance in the design of future experimental protocols.

Analysis of u-AQP2, an index of the renal response to AVP, revealed that while under basal condition u-AQP2 levels in the 24-hour urine samples were significantly higher in females than in males. However, after 10 min recovery from LBNP, u-AQP2 levels were not significantly different in both sexes; these levels remained significantly lower in males with respect to females after the LBNP. Although a decrease in u-AQP2 in parallel to AVP decrease was expected, it is possible that 10 min recovery time was not sufficient to detect significant differences with respect to the resting conditions. Alternatively, it is possible that under LBNP condition, there may be a dissociation between AQP2 excretion and AVP as has been reported in particular pathological conditions (Ranchin et al. 2010). However, as this study was carried out in healthy subject, no detectable u-AQP2 levels could have arisen due to the shorter time to recovery.

The cardiac natriuretic peptides, ANP and BNP are important regulators of the homeostatic control of blood pressure, salt and water balance. They can be considered biomarkers of cardiac health due to the close relationship between plasma concentrations of these peptides and “cardiac load”. In our experiment, BNP did not show any significant alteration when the raw data were analyzed. Only when the data were normalized as percentage of the baseline values, and presyncopal subjects were included a significant increase at the end of the recovery period was seen but only in the female subjects.

ADM, a vasodilator peptide hormone, largely expressed throughout the cardiovascular system plays a key role in the regulation of cardiovascular function (Nishikimi et al. 2013). ADM has a powerful vasodilatory effect especially in the kidney, brain and lung and several vasoconstrictive agents have been shown to elevate its concentrations, among them norepinephrine, aldosterone and angiotensin II. These observations suggest that ADM may serve to counterbalance the vasoconstrictive effects of these substances (Wong et al. 2012, Nagaya et al. 2000). An interesting finding in this respect is the observation that ADM increases cerebral baroreceptor reflex response in rats (Ho et al. 2008). Furthermore, its other effects include increasing the cardiac output, apparently via an inotropic effect (Nagaya et al. 2000).

It has been reported that head-up-tilt (HUT) over 30° leads to a significant increase of plasma ADM within as little as 2 minutes correlating with the degree of HUT, thus indicating that ADM might play a significant role in quick adaptation to orthostatic loadings (Roessler et al. 1999).. In Roessler's study, ADM continued to increase until the end of HUT after 30 minutes and rapidly returned to baseline levels within 3 minutes after the return to supine position. The physiological stimulus by which the ADM release was triggered in this study could be central hypovolemia caused by upright posture or LBNP detected via tension receptors in the right atrium and triggering ADM release in a cardio renal mechanism highly like the one triggering the release of AVP. It must be said however, that ADM's effects on cardiovascular regulation are complex and still poorly understood. In our experiment, no significant alterations of ADM were shown, even though LBNP reduces venous return to the heart and therefore should at least in theory influence ADM release. It should be noted that if presyncopal subject were included there was a significant increase, but only in the males. At the same time including the presyncopal subjects and normalizing the BNP data led to a significant increase only in the females. This raises the question whether males and females might respond to alterations in orthostatic loading via different mechanisms. Unfortunately, the fact that these observations do not appear when presyncopal subjects were excluded makes it necessary to conduct further research to sufficiently test this hypothesis.

### ***Conclusions and future directions***

Overall, the analysis of volume regulating hormones suggest that central hypovolemia induced by LBNP should stimulate afferent inputs to the brain leading to AVP release while soon after the end of central hypovolemia an inhibition of AVP release should take place. The fact that this was not observed in our study is consistent with most evidence indicating this response taking place only under conditions of higher levels of central hypovolemia than the ones caused by the LBNP strength we used. Analysis of BNP and ADM raise the possibility of a preferential adaptive vascular response to central hypovolemia in males as shown by the normalized increase in ADM, whereas females showed a preferential renal response as shown by the normalized increase in BNP. Furthermore, our results suggest that there might be a difference between men and women in the Copeptin response to alterations in orthostatic loading, simulated either by using LBNP or

during posture changes. Future studies should examine the role of ADM and BNP in both sexes under conditions of orthostatic stress and the level of central hypovolemia needed to elicit an AVP response.

### **Acknowledgements**

We thank the participants for their time and co-operation.

### **Financial support**

This study was supported by ASI (Italian Space Agency, grant number 2013-091-R.0) to FCS and GV.

### **Conflict of interest declaration**

None declared

## References

- Alboni, P. and R. Furlan, Eds., „Vasovagal Syncope“, NY: Springer, 2014, p.44f.
- Angeletti, S., G. Dicunzio, M. Fioravanti, M. Cesaris, M. Fogolari, A. Lo Presti, M. Ciccozzi, L. De Florio (2015) “Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test Combination“. *Disease Markers* 11/2015 p.1-14
- Bankir, L., D. G. Bichet and N. G. Morgenthaler (2017). "Vasopressin: physiology, assessment and osmosensation." *J Intern Med* 282(4): 284-297
- Barat,C., L. Simpson, and E. Breslow (2004) “Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus,” *Biochemistry (Mosc.)*, vol. 43, no. 25, pp. 8191–8203
- Bichet D.G (2016) “Vasopressin at Central Levels and Consequences of Dehydration” *Ann Nutr Metab* 2016;68(suppl 2):19-23
- Cignarelli, M., G. De Pergola, A. Paternostro, M. Corso, M. R. Cospite, G. M. Centaro, and R. Giorgino (1986) “Arginine-vasopressin response to supine-erect posture change: an index for evaluation of the integrity of the afferent component of baroregulatory system in diabetic neuropathy,” *Diabète Métabolisme*, vol. 12, no. 1, pp. 28–33
- Convertino,V. A., L. D. Tripp, D. A. Ludwig, J. Duff, and T. L. Chelette (1998) “Female exposure to high G: chronic adaptations of cardiovascular functions,” *Aviat. Space Environ. Med.*, vol. 69, no. 9, pp. 875–882
- Crofton,J.T., H. Dustan, L. Share, and D. P. Brooks (1986) “Vasopressin secretion in normotensive black and white men and women on normal and low sodium diets,” *J. Endocrinol.*, vol. 108, no.2, pp. 191–199
- de Bree, F. M. and J. P. Burbach (1998) “Structure-function relationships of the vasopressin prohormone domains,” *Cell. Mol. Neurobiol.*, vol. 18, no. 2, pp. 173–191
- Dobsa, L. and K. C. Edozien( 2013) ”Copeptin and its potential role in diagnosis and prognosis of various diseases,” *Biochem. Medica*, vol. 23, no. 2, pp. 172–190

Forsling, M. L., P. Strömberg, and M. Åkerlund (1982) "Effect of ovarian steroids on vasopressin secretion," *J. Endocrinol.*, vol. 95, no. 1, pp. 147–151

Franke, W. D., C. P. Johnson, J. A. Steinkamp, R. Wang, and J. R. Halliwill (2003) "Cardiovascular and autonomic responses to lower body negative pressure: do not explain gender differences in orthostatic tolerance," *Clin. Auton. Res. Off. J. Clin. Auton. Res. Soc.*, vol. 13, no. 1, pp. 36–44

Fu, Q., A. Arbab-Zadeh, M. A. Perhonen, R. Zhang, J. H. Zuckerman, and B. D. Levine (2004) "Hemodynamics of orthostatic intolerance: implications for gender differences," *Am. J. Physiol. Heart Circ. Physiol.*, vol. 286, no. 1, pp. H449–457

Goldsmith, S.R., G. S. Francis, A. W. Cowley, and J. N. Cohn (1982) "Response of vasopressin and norepinephrine to lower body negative pressure in humans," *Am. J. Physiol. - Heart Circ. Physiol.*, vol. 243, no. 6, pp. H970–H973

Goswami, N, J.A. Loeppky, H. Hinghofer-Szalkay (2008) „LBNP: past protocols and technical considerations for experimental design. *Aviat Space Environ Med.* 2008; 79(5): 459-471

Hinghofer-Szalkay, H., H. K. Lackner, A. Rössler, B. Narath, A. Jantscher, and N. Goswami (2011) "Hormonal and plasma volume changes after presyncope," *Eur. J. Clin. Invest.*, vol. 41, no. 11, pp. 1180–1185

Ho LK, Chen K, Ho IC, Shen YC, Yen DH, Li FC, Lin YC, Kuo WK, Lou YJ, Yen JC (2008) "Adrenomedullin enhances baroreceptor reflex response via cAMP/PKA signaling in nucleus tractus solitarius of rats," *Neuropharmacology.* Oct;55(5):729-36

Holwerda, D. A. (1972) "A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization," *Eur. J. Biochem. FEBS*, vol. 28, no. 3, pp. 334–339

Hunt, P. J., T. G. Yandle, M. G. Nicholls, A. M. Richards and E. A. Espiner (1995) "The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma." *Biochem Biophys Res Commun* 214(3): 1175-1183

Janda, S. and J. Swiston (2010) "Diagnostic accuracy of pleural fluid NT-pro-BNP for pleural effusions of cardiac origin: a systematic review and meta-analysis," *BMC Pulm Med.* 2010 Nov 20;10:58

Jarvis, S. S., J. P. Florian, M. J. Curren, and J. A. Pawelczyk (2010) "Sex differences in vasoconstrictor reserve during 70 deg head-up tilt," *Exp. Physiol.*, vol. 95, no. 1, pp. 184–193

Johnson, B.D., N. van Helmond, T. B. Curry, C. M. van Buskirk, V. A. Convertino, and M. J. Joyner (2014) "Reductions in central venous pressure by lower body negative pressure or blood loss elicit similar hemodynamic responses," *J. Appl. Physiol.* Bethesda Md 1985, vol. 117, no. 2, pp. 131–141

Kato, J, T. Etoh, K. Kitamura, T. Eto (2005) "Atrial and Brain Natriuretic Peptides as Markers of Cardiac Load and Volume Retention in Primary Aldosteronism" *Am J Hypertens.* 2005 Mar;18(3):354-7

Koch, G. and I. Schnyder (2015) "Model for characterizing copeptin kinetics and response in healthy subjects," [Online]. Available: <http://www.page-meeting.org/?abstract=3501>. [Accessed: 25-Aug-2015]

Koshimizu, T., K. Nakamura, N. Egashira, M. Hiroyama, H. Nonoguchi, and A. Tanoue (2012) "Vasopressin V1a and V1b receptors: from molecules to physiological systems," *Physiol. Rev.*, vol. 92, no. 4, pp. 1813–1864

Krishnan, B., M. Patarroyo-Aponte, D. Duprez, M. Pritzker, E. Missov, D.G.Benditt (2015) "Orthostatic hypotension of unknown cause: Unanticipated association with elevated circulating N-terminal brain natriuretic peptide (NT-proBNP)" *Heart Rhythm.* 2; 12(6):1287-94

Laycock, J. F. "Perspectives on Vasopressin" London: Hackensack, NJ: Imperial College Press, 2010, p.5ff.

Levine, B. D., L. D. Lane, J. C. Buckey, D. B. Friedman, and C. G. Blomqvist (1991) "Left ventricular pressure-volume and Frank-Starling relations in endurance athletes. Implications for orthostatic tolerance and exercise performance," *Circulation*, vol. 84, no. 3, pp. 1016–1023

Meendering, J. R., B. N. Torgrimson, B. L. Houghton, J. R. Halliwill, and C. T. Minson (2005) "Menstrual cycle and sex affect hemodynamic responses to combined orthostatic and heat stress," *Am. J. Physiol. Heart Circ. Physiol.*, vol. 289, no. 2, pp. H631–642, Aug

Mohanty, S., and G. Asha (2015) "A novel stress neurohormone copeptin: its potential role in diagnosis and prognosis of various diseases". [Online] Available:[http://www.wjpr.net/dashboard/abstract\\_id/2075](http://www.wjpr.net/dashboard/abstract_id/2075). [Accessed: 06-Apr-2016]

Morgenthaler, N. G., J. Struck, C. Alonso and A. Bergmann (2006) "Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin." *Clin Chem* 52(1): 112-119

Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K. (2000) „Hemodynamic, Renal, and Hormonal Effects of Adrenomedullin Infusion in Patients With Congestive Heart Failure.“ *Circulation*. 2000 Feb 8;101(5):498-503

Nedvetsky, P. I., G. Tamma, S. Beulshausen, G. Valenti, W. Rosenthal and E. Klusmann (2009) "Regulation of aquaporin-2 trafficking." *Handb Exp Pharmacol*(190): 133-157

Nickel, C. H., R. Bingisser, and N. G. Morgenthaler (2012) "The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department," *BMC Med.*, vol. 10, no. 1, p. 7

Nishikimi, T., K. Kuwahara, Y. Nakagawa, K. Kangawa and K. Nakao (2013) "Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application." *Curr Protein Pept Sci* 14(4): 256-267

Norsk, P., P. Ellegaard, R. Videbaek, C. Stadeager, F. Jessen, L. B. Johansen, M. S. Kristensen, M. Kamegai, J. Warberg, and N. J. Christensen (1993) "Arterial pulse pressure and vasopressin release in humans during lower body negative pressure," *Am. J. Physiol.*, vol. 264, no. 5 Pt 2, pp. R1024–1030

Pump, B., A. Gabrielsen, N. J. Christensen, P. Bie, M. Bestle, and P. Norsk (1999) "Mechanisms of inhibition of vasopressin release during moderate antiorthostatic posture change in humans," *Am. J. Physiol.*, vol. 277, no. 1 Pt 2, pp. R229–235

Rademaker, M. T. and A. M. Richards (2005) "Cardiac natriuretic peptides for cardiac health" *Clin Sci (Lond)* 108(1): 23-36

Ranchin B, Boury-Jamot M, Blanchard G, Dubourg L, Hadj-Aïssa A, Morin D, Durroux T, Cochat P, Bricca G, Verbavatz JM, Geelen G (2010) „Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion“ *J Clin Endocrinol Metab*. 2010 Sep;95(9):E37-43

Repaske, D. R., R. Medlej, E. K. Gultekin, M. R. Krishnamani, G. Halaby, J. W. Findling and J. A. Phillips, 3rd (1997) "Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1-->Val in the signal

peptide of the arginine vasopressin/neurophysin II/copeptin precursor." *J Clin Endocrinol Metab* 82(1): 51-56

Rössler, A., Z. László, B. Haditsch, H.G. Hinghofer-Szalkay (1999) „Orthostatic Stimuli Rapidly Change Plasma Adrenomedullin in Humans“. *Hypertension*. 1999 Nov;34(5):1147-51

Rössler, A., N. Goswami, B. Haditsch, J. A. Loeppky, F. C. Luft, and H. Hinghofer-Szalkay (2011) “Volume regulating hormone responses to repeated head-up tilt and lower body negative pressure,” *Eur. J. Clin. Invest.*, vol. 41, no. 8, pp. 863–869

Rose, B. D., “Clinical Physiology of Acid-Base and Electrolyte Disorders.” 5. A. New York: Mcgraw-Hill Education Ltd, 2000, p.190

Roussel,R., L. Fezeu, M. Marre, G. Velho, F. Fumeron, P. Jungers, O. Lantieri, B. Balkau, N. Bouby, L. Bankir, and D. G. Bichet (2014) “Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease,” *J. Clin. Endocrinol. Metab.*, vol. 99, no. 12, pp. 4656–4663

Russomano, T., F. May, G. Dalmarco, and R. R. Baptista (2015) “A Gender comparison of Cardiovascular Responses to Lower Body Negative Pressure Exposure,” *Am. J. Med. Biol. Res.*, vol. 3, no. 4, pp. 95–101

Schnyder,I., K. Strausz, G. Koch, C. Walti, M. Pfister, B. Allolio, W. K. Fenske, and M. Christ-Crain (2015) “Physiological area of normality of copeptin in normal-to-hyperosmolar states” *Endocr.Abstr.*[Online].Available: <https://www.endocrine-abstracts.org/ea/0037/ea0037EP706> [Accessed: 14-Jul-2018]

Share, L., J. T. Crofton, and Y. Ouchi (1988) “Vasopressin: sexual dimorphism in secretion, cardiovascular actions and hypertension,” *Am. J. Med. Sci.*, vol. 295, no. 4, pp. 314–319

Stachenfeld, N. S., L. DiPietro, S. F. Palter, and E. R. Nadel (1998) “Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women,” *Am. J. Physiol.*, vol. 274, no. 1 Pt 2, pp. R187–195

Suzuki T, Yamazaki T, Yazaki Y(2001) “The role of the natriuretic peptides in the cardiovascular system,” *Cardiovasc Res*. 2001 Aug 15;51(3):489-94

Tamma, G., N. Goswami, J. Reichmuth, N.G. de Santo, G. Valenti (2015) “Aquaporins, vasopressin, and aging: current perspectives,” *Endocrinology* 156(3):777-88

Tamma, G., A. Di Mise, M. Ranieri, M. Svelto, R. Pisot, G. Bilancio, P. Cavallo, N. G. De Santo, M. Cirillo and G. Valenti (2014) "A decrease in aquaporin 2 excretion is associated with bed rest induced high calciuria," *J Transl Med* 12: 133

Trimarco B., N. de Luca, A. de Simone, M. Volpe, B. Ricciardelli, G. Lembo, M. Condorelli (1987) "Impaired control of vasopressin release in hypertensive subjects with cardiac hypertrophy," *Hypertension*. 1987 Dec;10(6):595-602

Tsuchihashi, T., M. Ueno, H. Muratani, Y. Tomita, S. Takishita, and M. Fujishima (1989) "Effects of Sodium Depletion and Orthostasis on Plasma and Urinary Vasopressin in Normal Subjects," *Endocrinol. Jpn.*, vol. 36, no. 2, pp. 237–243

Valenti, G., A. Laera, G. Pace, G. Aceto, M. L. Lospalluti, R. Penza, F. P. Selvaggi, M. L. Chiozza and M. Svelto (2000) "Urinary aquaporin 2 and calciuria correlate with the severity of enuresis in children." *J Am Soc Nephrol* 11(10): 1873-1881

Vokes, T. J., N. M. Weiss, J. Schreiber, M. B. Gaskill, and G. L. Robertson (1988) "Osmoregulation of thirst and vasopressin during normal menstrual cycle," *Am. J. Physiol.*, vol. 254, no. 4 Pt 2, pp. R641–647

Wang, Y.X., Crofton, J.T., Share, L. (1997) "Sex differences in the cardiovascular and renal actions of vasopressin in conscious rats." *Am J Physiol* 1997 Jan;272(1 Pt 2):R370-6

Waters, W. W., M. G. Ziegler, and J. V. Meck (2002) "Postspaceflight orthostatic hypotension occurs mostly in women and is predicted by low vascular resistance," *J. Appl. Physiol.* Bethesda Md 1985, vol. 92, no. 2, pp. 586–594

White, D. D., R. W. Gotshall, and A. Tucker (1996). "Women have lower tolerance to lower body negative pressure than men," *J. Appl. Physiol.* Bethesda Md 1985, vol. 80, no. 4, pp. 1138–1143

Wong LL, Verbalis JG (2002) "Systemic diseases associated with disorders of water homeostasis" *Endocrinology and Metabolism Clinics of North America*. 31: 121-40

Wong, H.K., Cheung T.T., Cheung B.M. (2012) "Adrenomedullin and cardiovascular diseases." *JRSM Cardiovasc Dis*. 2012 Aug 10;1(5)

## LEGEND TO FIGURES

**Figure 1:** Experimental Protocol. The yellow arrows indicate blood collection times.

**Figure 2:** Subject undergoing LBNP. Electrodes for electrocardiogram and thoracic impedance for monitoring the vital parameters are attached to the patient's chest. A Device for continuous measuring of blood pressure is attached to the right arm.

**Figure 3:** Copeptin in Males and Females. A Wilcoxon test yielded a significant decrease between baseline and recovery for men (\*\* $p < 0.01$ ) and women (\* $p < 0.05$ ) and no significant difference between Baseline and End of LBNP or End of LBNP and Recovery. A Mann-Whitney U test yielded a significant sex difference at Baseline (\* $p < 0.05$ ), End of LBNP (\* $p < 0.05$ ) and End of Recovery (\*\* $p < 0.01$ ) period. Values are expressed as means  $\pm$  SD.

**Figure 4:** Urinary levels of aquaporin 2 (uAQP2) in females and males, expressed as protein to-urinary creatinine (UrCr, in mg) ratio. A. u-AQP2 excretion was significantly higher in females with respect to males at baseline (\*\* $p < 0,0001$ ). B. u-AQP2 levels did not change significantly after 10 min recovery (\*\* $p < 0.0001$  vs females initial, \*\* $p < 0.001$  vs females final). Values are expressed as means  $\pm$  SD.

	Age	Weight	Height	BMI
Males (n=19)	25.85 ± 3.47 years	79.35 ± 9.86 kg	181.40 ± 5.44 cm	24.06 ± 2.28 kg/m <sup>2</sup>
Females (n=18)	24.28 ± 3.43 years	60.94 ± 8.61 kg	167.78 ± 5.29 cm	21.57 ± 2.07 kg/m <sup>2</sup>

Table 1 Principal characteristics of participants




Fig. 1



Fig. 2

	Baseline	End of LBNP	End of Recovery
<b>BNP:</b>			
Males (n=15)	21.92 ± 16,76	19.68 ± 16,18	24.42 ± 20,21
Females (n=6)	19.24 ± 10,97	24.8 ± 19,29	25.66 ± 17,45
<b>ADM:</b>			
Males (n=14)	4,49 ± 2,93	4,78 ± 2,68	5,31 ± 2,81
Females (n=8)	3,15 ± 2,44	3,53 ± 2,21	3,57 ± 2,71
<b>Copeptin:</b>			
Males (n=15)	281.56 ± 116,20	236,16 ± 83,42	211,86 ± 50,13 **
Females (n=9)	199.70 ± 77,63	169,14 ± 68,51	152,05 ± 46,415 *
<b>AVP:</b>			
Males (n=14)	2,40 ± 1,30	2,21 ± 0,69	2,16 ± 0,51
Females (f=7)	1,98 ± 0,84	2,97 ± 2,11	2,68 ± 2,036
<b>ACTH:</b>			
Males (n=15)	8.832 ± 5,62	10.04 ± 4,84	10.65 ± 6,05
Females (n=9)	9.085 ± 5,02	11.08 ± 7,51	8.088 ± 5,59

**Difference from baseline: (\*p<0.05 \*\*p<0.01)**

Table 2 Hormonal data at different timepoints during the protocol

### Copeptin, Sex and Protocol Stage





Fig. 3

### A Basal urinary levels of aquaporin 2



### B Urinary aquaporin 2, Sex and Protocol Stage




Fig 4